Aug 10, 2017 03:26 PM IST | Source:

Hold Natco Pharma; target of Rs 955: ICICI Direct

ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 955 in its research report dated August 09, 2017.

  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Natco Pharma

Revenues grew 31% YoY to Rs 445 crore (I-direct estimate: Rs 396 crore) mainly due to profit sharing from Oseltamivir sales in the US and robust export API sales EBITDA margins improved 801 bps YoY to 30.7% (I-direct estimate: 27.5%) mainly due to a favourable product mix. EBITDA grew 77% to Rs 137 crore (I-direct estimate: Rs 109 crore) Adjusted net profit increased 96% YoY to Rs 93 crore (I-direct estimate: Rs 68 crore) mainly on account of a strong operational performance.


Like FY17, Q1 also witnessed a windfall of Oseltamivir profit sharing for which the company enjoyed exclusivity. However, this was partly offset by GST transition impact in domestic sales. Going forward, the Hepatitis C group continues to be the main catalyst for growth. This augurs well in the long run as it will complement the oncology franchisee. Despite possible crowding in the Hepatitis C space, we expect the product to generate significant cash flows from India and other emerging markets. On the exports front, the US would remain a key long term driver base on its strong complex FTF/Para IV filings. We continue to value the stock on an SOTP basis to capture the emerging FTF/limited competition opportunities in the US. Our new target price is ~Rs 955, which includes base business value of ~Rs 400 (25x FY19E EPS of Rs 16) + ~Rs 555 for NPV of other FTF/Para IVs.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Follow us on
Available On